Grade 5 adverse events (excluding progressive disease) · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
Next‐generation ALK inhibitor showed no clear difference in grade 5 adverse events (excluding progressive disease) compared with crizotinib (low certainty).
1 finding from 1 review
Adverse events: occurring in at least 10% of cavosonstat treated participants · adults and children with cystic fibrosis
1 finding from 1 review
Adverse events: most commonly occurring events (occurring in at least 10% of participants) · adults and children with cystic fibrosis
1 finding from 1 review
Adverse events ‐ treatment emergent · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype
Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor showed no clear difference in adverse events: number of participants with treatment‐emergent… compared with control (ivacaftor alone or tezacaftor plus ivacaftor) (moderate certainty).
1 finding from 1 review
Adverse events experienced at short or long term ‐ general adverse events 24 weeks' · patients with schizophrenia
It is very uncertain whether COMPARISON 1: CBT+ STANDARD CARE changes adverse events: General: any adverse event compared with STANDARD CARE ALONE (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events · adults and children with generalised tonic‐clonic seizures with or without other seizure types
1 finding from 1 review
Serious adverse events ( · Individuals with peripheral arterial disease
Growth factors showed no clear difference in serious adverse events ( compared with placebo or no therapy (moderate certainty).
1 finding from 1 review
Adverse events ‐ treatment emergent · adults with seasonal affective disorder
Fluoxetine showed no clear difference in adverse events (at least 1 treatment‐emergent adverse event) compared with light therapy (low certainty).
1 finding from 1 review
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
1 finding from 1 review
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
It is very uncertain whether adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver… changes adverse events considered non‐serious (number of participants) compared with liver transplantation (very low certainty).
1 finding from 1 review
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
It is very uncertain whether E1B‐deleted (dl1520) adenovirus changes adverse events considered non‐serious (number of participants) compared with percutaneous ethanol injection (very low certainty).
1 finding from 1 review
Proportion of people with ≥ 1 serious adverse events during treatment · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with ≥ 1 serious adverse events during treatment · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found